Price
No data yet.
Social Signal Score
Analyst Ratings
1 analystRevenue
$356.00M+59.64%Company Profile
- CEO
- Mark Crossley
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 1,000
- Beta
- -0.06
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 2.84
Financials
Revenue
$356.00M+59.6%Net Income
$137.00M+280.6%EBITDA
$185.00M+270.0%Free Cash Flow
$83.00M-49.7%EPS (diluted)
$1.12+348.0%Shares Outstanding (diluted)
122.00M-13.2%Operating Expenses
$124.00MCash & Debt
$305.00MReturn of Capital
$462.3KDividend per Share
$0.47Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.24B | $210.00M | $1.68 |
| 2024 | $1.19B | $2.00M | $0.02 |
| 2023 | $1.09B | $-129.00M | $-0.94 |
| 2022 | $901.00M | $-44.00M | $-0.37 |
| 2021 | $791.00M | $205.00M | $1.38 |
| 2020 | $647.00M | $-148.00M | $-1.08 |
| 2019 | $785.00M | $134.00M | $0.95 |
| 2018 | $959.92M | $262.67M | $1.81 |
| 2017 | $1.15B | $60.92M | $0.42 |
| 2016 | $968.89M | $32.05M | $0.22 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from INVVY's reported EPS growth of 25.3% a year over 9 years.
- EPS in 5 years
- $5.19
- Implied price
- $108.96
- Return from $21.85
- 37.9% a year
To earn 15.0% a year on these assumptions you'd need to buy at $54.17 — today's price is already 59.7% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 15 | 18 | 21 | 24 | 27 |
|---|---|---|---|---|---|
| 15.3% | 18.6% | 23.0% | 26.9% | 30.3% | 33.4% |
| 20.3% | 23.8% | 28.4% | 32.4% | 36.0% | 39.2% |
| 25.3% | 28.9% | 33.7% | 37.9% | 41.6% | 45.0% |
| 30.3% | 34.1% | 39.1% | 43.4% | 47.3% | 50.8% |
| 35.3% | 39.2% | 44.4% | 48.9% | 52.9% | 56.6% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
100+25.00%Social Signal Score
Mentions (7)
- Newsglobenewswire.com·20d ago·Neutral
Supernus and Indivior Complete Merger Creating a Diversified CNS Biopharmaceutical Leader ROCKVILLE, Md., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Supernus, Inc. (Nasdaq: SUPN)1 today announced the successful completion of the merger between Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc. (Indivior). The combination officially launches Supernus, Inc., a leading diversified biopharmaceutical company dedicated to treating those living with central nervous system (CNS) diseases.
View source ↗ - Newsglobenewswire.com·24d ago·Neutral
Indivior Reports Third Quarter 2026 Financial Results Q3'26 Total Net Revenue of $ 356 Million, Up 13% YoY Record Quarterly Total SUBLOCADE® Net Revenue of $ 267 Million in Q3'26, Up 22% YoY Record Quarterly Net Income of $ 137 Million and Record Non-GAAP Net Income of $ 161 Million in Q3'26 Record Quarterly Adjusted EBITDA of $ 211 Million in Q3'26, Up 76% YoY Net Income Margin of 39%, up 2,500 basis points YoY, Adjusted EBITDA Margin of 59% , Up 2,100 Basis Points YoY On Track to Close Merger
View source ↗ - Newsglobenewswire.com·34d ago·Neutral
Indivior to Report Third Quarter 2026 Financial Results RICHMOND, Va., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will report its third quarter 2026 financial results on Thursday, October 29, 2026. The results will be released at 7:00 a.m. U.S. EDT and will be available on the Company's website at www.indivior.com.
View source ↗ - Newsglobenewswire.com·58d ago·Neutral
Addex Regains Rights to GABAB Positive Allosteric Modulator Portfolio from Indivior Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 25, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company developing novel small molecule allosteric modulators for neurological disorders, today announced that it has regained full global rights to all GABAB positive allosteric modulator (PAM) assets discovered under its research collaboration w
View source ↗ - Newsglobenewswire.com·66d ago·Negative
Indivior Pharmaceuticals, Inc. Declares Special Cash Dividend RICHMOND, Va., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) (“Indivior”) today announced that its Board of Directors declared a special cash dividend (the "Special Dividend") in the amount of (i) $8.13 per share of Indivior common stock payable to holders of record of the issued and outstanding Indivior common stock as of October 30, 2026 (the “Special Dividend Record Date”) (such holders, the “Spec
View source ↗ - Newsbusinesswire.com·85d ago·Negative
INDV Stock Alert: Halper Sadeh LLC is Investigating Whether Indivior Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Indivior Pharmaceuticals, Inc. (NASDAQ: INDV) and Supernus Pharmaceuticals, Inc. Upon closing of the Proposed Transaction, Indivior shareholders will own approximately 56.5% of the combined company.Halper Sadeh encourages Indivior shareholders to click here
View source ↗ - Newszacks.com·93d ago·Negative
Indivior's Supernus Merger Could Broaden Its Growth Engine in 2026 INDV's proposed Supernus merger could broaden its CNS portfolio, cut costs and reduce reliance on Sublocade, but closing remains uncertain.
View source ↗
Insider trading
Open-market buys and sells by INVVY officers and directors.
No open-market trades in the recent filings. All 100 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
100 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in INVVY.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
